Skip to content
Disclosery

EXANE DERIVATIVES: CMA position timeline

Available 13F reports, 13D and 13G stakes and each Form 3, 4 and 5 line of EXANE DERIVATIVES on CMA, newest first. How the timeline and the estimate are built.

EXANE DERIVATIVES held 1,309 CMA shares at 2022-06-30 per its 13F-HR filed 2022-07-12.

the latest 13F is the newest step

  1. period ended2022-06-30
    13F 1,309 shares
    Change vs previous 13F -205 shares

    0.06% of the 13F portfolio, value $96,044.

    13F-HR 0001623883-22-000006 filed by EXANE DERIVATIVES
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).

  2. period ended2022-03-31
    13F 1,514 shares
    Change vs previous 13F -13 shares

    0.04% of the 13F portfolio, value $136,909.

    13F-HR 0001623883-22-000004 filed by EXANE DERIVATIVES
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).

  3. period ended2021-12-31
    13F 1,527 shares
    Change vs previous 13F -902 shares

    0.03% of the 13F portfolio, value $132,851.

    13F-HR 0001623883-22-000002 filed by EXANE DERIVATIVES
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).

  4. period ended2021-09-30
    13F 2,429 shares
    Change vs previous 13F +428 shares

    0.05% of the 13F portfolio, value $195,537.

    13F-HR 0001623883-21-000008 filed by EXANE DERIVATIVES
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).

  5. period ended2021-06-30
    13F 2,001 shares
    Change vs previous 13F +959 shares

    0.03% of the 13F portfolio, value $137,950.

    13F-HR 0001623883-21-000006 filed by EXANE DERIVATIVES
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).

  6. period ended2021-03-31
    13F 1,042 shares
    Change vs previous 13F not available

    0.02% of the 13F portfolio, value $74,754.

    13F-HR 0001623883-21-000004 filed by EXANE DERIVATIVES
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).